Evidence map›Paper›PMID 42567521›Full record

ArticleThe Journal of biological chemistry2026

BAP1 and UTX are dispensable for transcription-driven Polycomb erasure but essential for enhancer establishment.

Meihan Gong, Xuanyuan Li, Shaomei Chen, Xudong Wu

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Meihan GongTianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China; State Key Laboratory of Experimental Hematology, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Tianjin Key Laboratory of Medical Epigenetics, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
Xuanyuan LiTianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China; Department of Cell Biology, Tianjin Medical University, Tianjin, China.
Shaomei ChenTianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China; Department of Cell Biology, Tianjin Medical University, Tianjin, China.
Xudong WuTianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China; Department of Cell Biology, Tianjin Medical University, Tianjin, China. Electronic address: wuxudong@tmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polycomb group (PcG) proteins safeguard cell identity by maintaining target genes in a transcriptionally repressed state through depositing two histone marks, H2A lysine-119 ubiquitination (H2AK119ub1) and H3 lysine-27 trimethylation (H3K27me3). BAP1 and UTX are thought to erase these marks during transcription activation, but their exact roles remain unclear. Here, we observe a rapid loss of H2AK119ub1, followed by a reduction in H3K27me3 levels at promoters on transcription induction, coinciding with a swift dissociation of Polycomb repressive complexes (PRCs). With an acute degradation system, we show that neither BAP1 nor UTX is required for transcription activation or the dissolution of Polycomb group repressive marks, though BAP1 depletion leads to elevated steady-state H2AK119ub1 levels. Furthermore, while UTX regulates enhancer activation independently of its demethylase activity, BAP1 contributes to this process through a dual role: its scaffolding function supports MLL4 occupancy at nascent enhancers, whereas its catalytic activity restricts H2AK119ub1 accumulation that would otherwise impede enhancer maturation. Together, these findings establish that BAP1 and UTX are dispensable for transcription-driven erasure of Polycomb marks but are required for enhancer establishment, with BAP1 acting through coordinated scaffolding and catalytic mechanisms.

Indexed as

bivalent chromatinenhancer establishmenteraserH2AK119ubH3K27me3polycomb

Identifiers

PMID42567521
PMCPMC13570294

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.